Pomegranate extract (PE) loaded nanoparticles transdermal emulgel formulation could be used as a promising drug against solid breast carcinoma.
Nanomedicine is a developing method for treating different diseases where sub-micron particles (e.g., nanoparticles) are employed in medicine. Recent advances in nanotechnology have opened up unprecedented possibilities for the efficient delivery and protection of drugs. Solid lipid nanoparticles (SLNs) are a good choice for the delivery of anticancer drugs. These nanoparticles are composed of lipids and possess a high drug loading capacity, and their lipid core allow solubilize lipophilic anticancer drugs enhancing their therapeutic effectiveness. On the other hand, the transdermal drug delivery system is a technique that provides drug absorption via the skin and recently has been considered as an inspiring developing approach for targeting solid tumors.
In this work, Mahmoud H. Teaima and co-workers at the Cairo University in Egypt have prepared an optimized pomegranate extract loaded solid lipid nanoparticles (PE-SLNs) formula in a transdermal emulgel to study its antitumor effect. The in vivo evaluation in mice resulted in the effective delivery and the significant therapeutic effect of the nanoparticles with the production of the cancer cells death and the tumor tissue necrosis. Therefore, the optimized PE-SLNs transdermal emulgel formulation is presented as a promising delivery carrier for the biological active pomegranate extract against solid breast carcinoma.
Article: Efficacy of pomegranate extract loaded solid lipid nanoparticles transdermal emulgel against Ehrlich ascites carcinoma. doi:10.1016/j.nano.2021.102466